Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Nature Medicine, Journal Year: 2018, Volume and Issue: 24(10), P. 1550 - 1558

Published: Aug. 13, 2018

Language: Английский

---

A framework for advancing our understanding of cancer-associated fibroblasts

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(3), P. 174 - 186

Published: Jan. 24, 2020

Abstract Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling interactions cancer cells crosstalk infiltrating leukocytes. As such, they potential target for optimizing therapeutic strategies against cancer. However, many challenges present in ongoing attempts to modulate CAFs benefit. These include limitations our understanding origin heterogeneity CAF function, it being desirable retain some antitumorigenic functions. On basis meeting experts field biology, we summarize this Consensus Statement current knowledge framework advancing critical cell type within microenvironment.

Language: Английский

---

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Annals of Oncology, Journal Year: 2018, Volume and Issue: 30(1), P. 44 - 56

Published: Nov. 1, 2018

Treatment with immune checkpoint blockade (ICB) agents such as anti-programmed cell death protein 1 (PD-1), death-ligand (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated 4 (CTLA-4) can result in impressive response rates and durable disease remission but only a subset of patients cancer. Expression PD-L1 has demonstrated utility selecting for to ICB proven be an important biomarker patient selection. Tumor mutation burden (TMB) is emerging potential biomarker. However, refinement interpretation contextualization required.

Language: Английский

---

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 19(3), P. 133 - 150

Published: Feb. 12, 2019

Language: Английский

---

Single-cell reconstruction of the early maternal–fetal interface in humans

Nature, Journal Year: 2018, Volume and Issue: 563(7731), P. 347 - 353

Published: Nov. 8, 2018

Language: Английский

---

Macrophages as regulators of tumour immunity and immunotherapy

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 19(6), P. 369 - 382

Published: Feb. 4, 2019

Language: Английский

---

Regulation and Function of the PD-L1 Checkpoint

Immunity, Journal Year: 2018, Volume and Issue: 48(3), P. 434 - 452

Published: March 1, 2018

Language: Английский

---

Transforming Growth Factor-β Signaling in Immunity and Cancer

Immunity, Journal Year: 2019, Volume and Issue: 50(4), P. 924 - 940

Published: April 1, 2019

Language: Английский

---

Roles of the immune system in cancer: from tumor initiation to metastatic progression

Genes & Development, Journal Year: 2018, Volume and Issue: 32(19-20), P. 1267 - 1284

Published: Oct. 1, 2018

The presence of inflammatory immune cells in human tumors raises a fundamental question oncology: How do cancer avoid the destruction by attack? In principle, tumor development can be controlled cytotoxic innate and adaptive cells; however, as develops from neoplastic tissue to clinically detectable tumors, evolve different mechanisms that mimic peripheral tolerance order tumoricidal attack. Here, we provide an update recent accomplishments, unifying concepts, future challenges study tumor-associated cells, with emphasis on metastatic carcinomas.

Language: Английский

---

Inflammation and tumor progression: signaling pathways and targeted intervention

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: July 12, 2021

Abstract Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates progression treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation dendritic cells (DCs) antigen presentation, leading anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers activators transcription (JAK-STAT), toll-like receptor (TLR) cGAS/STING, mitogen-activated protein kinase (MAPK); factors, including cytokines (e.g., interleukin (IL), interferon (IFN), necrosis (TNF)-α), chemokines C-C motif chemokine ligands (CCLs) C-X-C (CXCLs)), growth factors vascular endothelial (VEGF), transforming (TGF)-β), inflammasome; well metabolites prostaglandins, leukotrienes, thromboxane, specialized proresolving mediators (SPM), have been identified pivotal regulators initiation resolution inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, SPM developed specifically modulate in cancer therapy, with some these already undergoing clinical trials. Herein, we discuss crosstalk between processes. We also highlight potential targets for harnessing cancer.

Language: Английский

---